Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)

Inclusion Criteria: * Signed informed consent form. * Men or women aged more than or equal to (≥) 18 years, and less than (\<) 75 years. * CML-CP/AP patients with the Ph chromosome or BCR-ABL1 fusion genes. * Patient with CML-CP/AP who are resistant to or intolerant to previous TKIs therapy. * ECOG performance status of 0-1 and no worsening within 2 weeks before the first dose. * Life expectancy ≥ 12 weeks. * Men or women should be using adequate contraceptive measures throughout the study; Females should not be breastfeeding at the time of screening, during the study and until 6 months after completion of the study. * Females must have evidence of non-childbearing potential. Exclusion Criteria: * CML-CP patients who have acquired CCyR and have not lost it. * Patients with CML-CP who have progressed to AP or blast phase(BP.) * Patients with CML-AP who have obtained CHR or no evidence of CML in peripheral blood. * Patients with CML-AP who have progressed to BP. * Previous treatment with a BCR-ABL1 TKI allosteric inhibitor . * Impaired cardiac function including any one of the following: * Resting corrected QT interval (QTc) \> 470 ms obtained from electrocardiogram (ECG), using the screening clinic's ECG machine and Fridericia's formula for QT interval correction (QTcF). * Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG. * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, * Left ventricular ej…